1. Two Epstein-Barr Virus–Related Serologic Antibody Tests in Nasopharyngeal Carcinoma Screening: Results From the Initial Phase of a Cluster Randomized Controlled Trial in Southern China.
- Author
-
Liu, Zhiwei, Ji, Ming-Fang, Huang, Qi-Hong, Fang, Fang, Liu, Qing, Jia, Wei-Hua, Guo, Xiang, Xie, Shang-Hang, Chen, Feng, Liu, Yue, Mo, Hao-Yuan, Liu, Wan-Li, Yu, Yuan-Long, Cheng, Wei-Min, Yang, You-Ye, Wu, Biao-Hua, Wei, Kuang-Rong, Ling, Wei, Lin, Xiao, and Lin, Er-Hong
- Subjects
NASOPHARYNX tumors ,EARLY detection of cancer ,RESEARCH ,BIOMARKERS ,BIOPSY ,BLOOD testing ,CHI-squared test ,CLUSTER analysis (Statistics) ,DISEASE susceptibility ,ENDOSCOPY ,ENZYME-linked immunosorbent assay ,EPSTEIN-Barr virus ,IMMUNOGLOBULINS ,MEDICAL cooperation ,RESEARCH funding ,STATISTICAL sampling ,RANDOMIZED controlled trials ,EARLY diagnosis ,DESCRIPTIVE statistics ,DIAGNOSIS - Abstract
A nasopharyngeal carcinoma (NPC) mass screening trial using a combination of immunoglobulin A antibodies to Epstein-Barr virus capsid antigen and nuclear antigen-1 by enzyme-linked immunosorbent assay in addition to indirect mirror examination in the nasopharynx and/or lymphatic palpation (IMLP) was conducted in southern China. Cantonese aged 30–59 years residing in 2 cities randomly selected by cluster sampling, Sihui and Zhongshan, were invited to participate in this screening from May 2008 through May 2010. Participants were offered fiberoptic endoscopy examination and/or pathologic biopsy if their serologic tests reached our predefined level of high risk or if results from the physical examination indicated possible cancer (i.e., were IMLP positive). A total of 28,688 individuals were voluntarily screened in the initial round. The overall NPC detection rate was 0.14% (41/28,688) with an early diagnosis rate of 68.3% (28/41) during the first year of follow-up. Thirty-eight of 41 cases (92.7%) were detected among the high-risk group, and 7 of 41 cases (17.1%) were detected among the IMLP-positive group. The 2 Epstein-Barr virus serologic tests by enzyme-linked immunosorbent assay could be a feasible alternative for NPC screening in endemic areas. Further follow-up is needed to examine whether screening has an effect on decreasing mortality from NPC in these areas. [ABSTRACT FROM PUBLISHER]
- Published
- 2013
- Full Text
- View/download PDF